NCT03146247

Analysis of the Pathogenesis of Itch in Response to Apremilast Therapy in Psoriasis Patients

• Status: Withdrawn
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Diamant Thaci · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study aims to identify and describe the presence of itch active molecules in psoriasis and response to treatment with apremilast. This data will be complemented by immunohistochemical data determining nerve ending density and neuropeptide concentrations before and during treatment and correlated with patient reported outcome. It is important to underscore that itch may interfere with various aspects of patient functioning, emotions and social status and should therefore be adequately addressed while treating patients with psoriasis

Conditions

• Moderate to Severe Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	Apremilast;Apremilast;Apremilast 10 MG; 20 MG; 30 MG Oral Tablet	All patients are scheduled to receive Apremilast with a titration phase of one week, followed by 23 weeks of regular treatment.

Timeline

• Start date: 2017-10-23
• Primary completion: 2019-03-01
• Completion: 2019-03-01
• First posted: 2017-05-09
• Last updated: 2019-04-18

Locations

1 site across 1 country: Germany